BMI1 and neoplasm: Considering that PTC596 can target both BMI1 and EZH2, it is recommended that in vitro and in vivo pre-clinical studies with pHGG cell lines be undertaken first to test for possible de-differentiation toward a more aggressive tumor phenotype.